Pharmacokinetic Study of 4 mg Nicotine Lozenge.: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Pharmacokinetic Study of 4 mg Nicotine Lozenge. (NCT01669122), a randomized phase 2 study. The primary outcome is Area Under the Curve From Time 0 to t, AUC (0-t).

2. Clinical Question

This is a pharmacokinetic comparison, not a trial of smoking cessation outcomes. Although Smoking Cessation is listed as a condition, the posted primary outcome concerns nicotine concentrations in plasma after dosing. Blood samples were collected over 12 hours after each dose. The comparison therefore concerns measured nicotine exposure under the study conditions, rather than a longer-term clinical outcome or an effect on smoking behavior.

3. Trial Design

This was a randomized, single-center, open-label, single-dose, four-way crossover study in fasted healthy male subjects. The registry lists the study as Phase 2 and reports enrollment of 40. The study began in 2012-06, primary completion was in 2012-08, and its status is completed.

In a crossover study, participants receive multiple treatments in different treatment sessions, so each participant can contribute observations under more than one treatment condition. This structure can help compare treatments within the same people, because stable differences between participants need not dominate the contrast. However, valid crossover analyses depend on the actual design and analysis model, including how treatment sequence, period, and within-person variation are handled. Those details are not reported in the registry record.

The four conditions were Test Lozenge (A), Test Lozenge (B), Test Lozenge (C), and Reference Lozenge. Each was described as a 4 mg nicotine lozenge given orally as a single dose per subject. Blood was collected before dosing and at scheduled times through 12 hours after dosing in each treatment session, and plasma samples were analyzed for nicotine levels.

The posted primary endpoint summaries are based on the per-protocol population. The displayed group sizes are 38 for Test Lozenge (A), 37 for Test Lozenge (B), 39 for Test Lozenge (C), and 38 for Reference Lozenge. The registry does not explain how participants were assigned to treatment sequences, whether there was a washout interval, or why the per-protocol group sizes differ. The trial’s original sample-size justification and its full statistical analysis plan are not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: A total of 102 participants were screened, of which only 40 were randomized into the study. Fourteen participants did not meet the study criteria, 32 were lost to follow up, 2 withdrew consent while remaining 14 were not randomized due to other reasons.

Period I

Reasons for not completing this period:

Washout Period I

Period II

Washout Period II

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Per protocol (PP) population: all randomized participants profiles, without a protocol deviation that would have lead to the data exclusion.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Area Under the Curve From Time 0 to t, AUC (0-t), measured over Blood samples were collected pre-dose and at 5, 10, 15, 30 and 45 minutes and 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hours post dosing.

The primary endpoint was Area Under the Curve From Time 0 to t, AUC(0-t), measured in nanograms (ng)*hours (h)/milliliter (mL). It represents the area under the plasma nicotine concentration-time profile from zero through the time of the last quantifiable sample. The registry says the endpoint was based on baseline-adjusted nicotine plasma concentration data.

AUC is used in pharmacokinetic studies as a measure of overall drug exposure across the sampled period. It combines concentration information across the collection times rather than focusing on a single measurement. In this study, blood sampling extended from pre-dose through 12 hours after dosing, with multiple measurements during that period. AUC(0-t) therefore describes exposure through the last quantifiable sample; it is distinct from AUC(0-inf), a secondary outcome that extends the exposure estimate to infinity.

The posted arm summaries report the mean and standard deviation for each lozenge group. A mean describes the group’s average endpoint value; the standard deviation describes variability among participant profiles. These summaries help characterize exposure and its spread, but they do not by themselves reveal the within-participant pattern created by the crossover design.

The endpoint is a pharmacokinetic measure, not a direct measure of smoking cessation or a clinical benefit. The registry record does not report an interpretation threshold for the size of an AUC difference, nor does it state a prespecified equivalence or non-inferiority margin. Those omissions limit what can be concluded about the practical meaning of a particular difference.

7. Results Posted in the Registry

• Test Lozenge (A): mean 89.14 versus 91.97 on control; difference -2.83 (95% CI -23.15 to 17.49), standardized effect d = -0.06; z-test p = 0.785.
• Test Lozenge (B): mean 87.38 versus 91.97 on control; difference -4.59 (95% CI -24.60 to 15.42), standardized effect d = -0.10; z-test p = 0.653.
• Test Lozenge (C): mean 86.60 versus 91.97 on control; difference -5.37 (95% CI -23.79 to 13.05), standardized effect d = -0.13; z-test p = 0.568.

8. Secondary Efficacy Endpoints

The registry also posts results for secondary outcomes. For each outcome below, the endpoint type, the test applied to the posted summary statistics, the result and its interpretation are given in turn. Secondary endpoints are usually not adjusted for multiple testing, so they support rather than confirm the primary finding.

AUC(0-inf)

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard deviations.
• Result:
  • Test Lozenge (A): mean 100.33 versus 104.53 on control; difference -4.20 (95% CI -32.48 to 24.08), standardized effect d = -0.07; z-test p = 0.771.
  • Test Lozenge (B): mean 98.90 versus 104.53 on control; difference -5.63 (95% CI -34.48 to 23.22), standardized effect d = -0.09; z-test p = 0.702.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Test Lozenge (A) and the control. The interval gives the range of effects that remain compatible with the data.
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Test Lozenge (B) and the control. The interval gives the range of effects that remain compatible with the data.

Rate of Elimination (Kel)

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard deviations.
• Result:
  • Test Lozenge (A): mean 0.26 versus 0.26 on control; difference 0.00 (95% CI -0.03 to 0.03), standardized effect d = 0.00; z-test p = 1.000.
  • Test Lozenge (B): mean 0.26 versus 0.26 on control; difference 0.00 (95% CI -0.03 to 0.03), standardized effect d = 0.00; z-test p = 1.000.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Test Lozenge (A) and the control. The interval gives the range of effects that remain compatible with the data.
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Test Lozenge (B) and the control. The interval gives the range of effects that remain compatible with the data.

Plasma Half Life (t1/2)

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard deviations.
• Result:
  • Test Lozenge (A): mean 2.86 versus 2.94 on control; difference -0.08 (95% CI -0.48 to 0.32), standardized effect d = -0.09; z-test p = 0.698.
  • Test Lozenge (B): mean 2.91 versus 2.94 on control; difference -0.03 (95% CI -0.48 to 0.42), standardized effect d = -0.03; z-test p = 0.896.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Test Lozenge (A) and the control. The interval gives the range of effects that remain compatible with the data.
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Test Lozenge (B) and the control. The interval gives the range of effects that remain compatible with the data.

The secondary pharmacokinetic outcomes extend the primary AUC(0-t) comparison by describing exposure beyond the last quantifiable sample, the timing of peak concentration, and elimination characteristics. The registry lists AUC(0-inf), time to maximum plasma concentration (Tmax), rate of elimination (Kel), and plasma half life. Posted secondary summaries are available for AUC(0-inf), Kel, and plasma half life; the Tmax results are not reported in the registry record.

Across the posted continuous secondary outcomes, the group means are generally close in scale across the three prototypes and the reference, while the standard deviations indicate variability. Sponsor-reported treatment-ratio analyses are present for AUC(0-inf) for A and B, but not for C. The registry does not report sponsor treatment-ratio analyses for the posted Kel or half-life outcomes. These endpoints add descriptive context to the primary exposure result, but they are not independent confirmations of it: all concern pharmacokinetic characteristics measured in the same study setting.

Secondary findings usually warrant more caution when multiple outcomes or treatment contrasts are examined. Each additional comparison creates more opportunities for an apparently notable result to arise by chance, particularly if analyses are selected after looking at the data. The registry does not report a multiplicity adjustment or a hierarchy for the secondary outcomes, so the posted secondary comparisons should be considered exploratory or supportive rather than treated as stand-alone confirmatory evidence.

The different outcomes also answer different questions. AUC(0-inf) concerns estimated total exposure, while Kel and half life describe elimination. None directly measures cessation behavior or a clinical outcome. The pattern across these measures can help characterize the pharmacokinetic profile, but it cannot replace the primary comparison or remedy missing details about the analysis plan. In particular, absence of a posted result for an outcome is not evidence of no difference; it means the result is not reported in the registry record.

Secondary outcomes registered for this trial, for reference (only those above were recalculated):

• AUC(0-inf)
• Time to Maximum Plasma Concentration (Tmax)
• Rate of Elimination (Kel)
• Plasma Half Life (t1/2)

9. Statistical Interpretation

10. Statistical Methods Explained

The registry reports continuous outcomes as means and standard deviations. A mean is the arithmetic average of the participant-level measurements in a group. A standard deviation describes how dispersed those measurements are around the average. The standard deviation is not the uncertainty of the mean: uncertainty also depends on sample size and, for this crossover study, on the relationships between repeated measurements from the same participants.

What does a mean difference represent?

The recalculated comparisons express each prototype’s mean minus the reference mean. A negative estimate means the posted prototype mean is lower than the posted reference mean; a positive estimate would mean it is higher. The estimates for the primary endpoint are -2.83, -4.59, and -5.37 for A, B, and C, respectively. These are simple unadjusted recalculations based on posted summary statistics. They are not a substitute for a crossover analysis that uses the participant-level treatment pattern.

A confidence interval gives a range of values compatible with the data and the assumptions used to calculate it. Its width reflects statistical precision: wider intervals indicate that a broader range of differences remains plausible. The primary recalculated intervals all include zero, but this does not prove the treatments are equal. Nor does a p-value above a conventional threshold establish equivalence. Equivalence requires a prespecified margin and an analysis that evaluates whether the interval lies within that margin.

Why does the crossover design matter?

In a crossover design, a participant can receive more than one treatment. A treatment comparison can then use within-person contrasts, which may be more precise than comparing unrelated groups when measurements from the same participant are correlated. The registry describes the design as crossover but does not report the statistical model, treatment sequence handling, period effects, or washout details. The recalculated mean differences use only the posted arm means, standard deviations, and group sizes. They do not incorporate paired differences or within-person covariance, so their intervals and p-values are not a reconstruction of the sponsor’s crossover analysis.

The sponsor’s reported treatment ratios are a separate form of analysis. A ratio of one represents equal values on the ratio scale. The posted ratios are 0.96, 0.96, and 0.94, each with a 90% confidence interval below one. The registry identifies these as non-inferiority or equivalence analyses, but does not state the precise method or the margin used to define an acceptable difference. Without that margin and analysis detail, the ratios and intervals can be described but cannot independently confirm a formal equivalence or non-inferiority conclusion.

What do the p-values tell the reader?

The p-values attached to the recalculated mean differences are unadjusted: 0.785, 0.653, and 0.568. They describe how inconsistent the observed estimates are with a null hypothesis of no difference under the calculation’s assumptions. They do not measure the probability that the null hypothesis is true, and they do not quantify the importance of an effect. They also do not incorporate any adjustment for multiple comparisons. The registry does not report p-values for the sponsor’s treatment-ratio analyses.

Because the calculation is unadjusted and based on independent group summaries, the p-values should be treated as descriptive rather than as the trial’s definitive crossover inference. If an analysis plan specifies a different model, especially one that accounts for repeated measurements, its inferential results take priority over these summary-statistic recalculations.

Why can variation matter?

Variability is substantial in the AUC summaries: standard deviations range from 36.19 to 45.6, while the means range from 86.6 to 91.97. When measurements vary widely, a modest difference between averages may be estimated less precisely unless the study has enough information to distinguish the difference from random variation. In crossover studies, the relevant precision also depends on how strongly a participant’s measurements under different treatments move together. That covariance is not reported in the registry record.

The endpoint summaries use the per-protocol population described by the registry. The registry does not provide a full account of exclusions, missing profiles, protocol deviations, or how missing observations were handled. It also does not report the original sample-size justification, interim analysis procedures, multiplicity strategy, or a detailed statistical plan. These missing details constrain any independent appraisal of the formal analysis.

11. Confidence Intervals and Precision

The recalculated 95% confidence intervals for mean AUC(0-t) differences are wide compared with the estimated differences. For A versus reference, the estimate is -2.83 and the interval extends from -23.15 to 17.49. For B, the estimate is -4.59 and the interval extends from -24.6 to 15.42. For C, the estimate is -5.37 and the interval extends from -23.79 to 13.05. Each interval includes zero, so the recalculated summaries do not rule out no mean difference. Each also includes values that would indicate a lower or a higher mean for the prototype.

Confidence intervals express uncertainty in the estimate under the assumptions of the calculation. They are not a range containing a fixed proportion of individual participant measurements, and they are not a guarantee that the true value falls inside a particular interval. Their breadth signals that these unadjusted comparisons do not locate the mean differences precisely.

The sponsor-reported treatment-ratio intervals are 90% intervals, not 95% intervals. For A and B, the estimate is 0.96, with interval 0.93 to 0.99; for C, the estimate is 0.94, with interval 0.91 to 0.97. These intervals are narrower on the reported ratio scale and lie below one. They arise from the sponsor’s reported analysis, whose method is not stated in the registry record. They cannot be substituted directly for the unadjusted mean-difference intervals because the estimates use different scales and analysis approaches.

Precision is also affected by the crossover structure and the available per-protocol profiles. The posted group summaries do not reveal within-person correlations, which could be important for a paired treatment comparison. The confidence intervals from the simple recalculation therefore describe a different, less design-specific calculation than the sponsor’s reported analysis. The registry does not report the prespecified margin needed to judge whether the sponsor intervals meet an equivalence or non-inferiority criterion.

12. Planning a Similar Trial: Sample Size

This is a planning illustration, not a re-evaluation of the original trial. It asks: if a new study wanted to detect a difference like the one observed, or a smaller one, how large would it need to be? It is deliberately not “observed power” of the finished trial, which is not a meaningful quantity.

The sample-size figures are planning illustrations based on the observed effect, not the original design justification for the trial. For these continuous outcomes, figures are participants per arm, not total events. The assumptions listed for the illustration are a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. Each row considers detecting a stated fraction of the observed effect. The registry’s own original design assumptions and sample-size justification are not reported in the registry record.

The 80% power column gives the illustrative number of participants per arm for a design with an 80% chance of detecting the specified effect if that effect is the true one and the assumptions hold. The 90% power column gives the corresponding number per arm for a design with a 90% chance. These are planning concepts, not guarantees about results in a future study; actual performance depends on the true effect, variability, analysis model, and other design features.

The rows labeled 100%, 75%, and 50% of the observed effect represent progressively smaller effects to detect. Smaller effects are harder to distinguish from random variation, so they require more participants under the same planning assumptions. The numbers can therefore rise sharply as the assumed effect becomes smaller. These figures should not be read as the sample size required to establish clinical equivalence: that would depend on a prespecified margin and an appropriate analysis.

These calculations are not observed power. Observed power is not a useful substitute for reading the estimated effect and its confidence interval. The study enrolled 40, while the illustrations derive from observed contrasts and are intended only to show how sample size changes under the stated assumptions. The crossover structure is also not captured by a simple equal-allocation two-arm illustration based on independent summaries.

13. How the Sample Size Is Derived

Power is the probability that a study of a given size rejects the null hypothesis when a specific true effect exists. It depends on four things: the effect to detect, the variability of the outcome, the significance level (here a two-sided α of 0.05, so z_1−α/2 = 1.960) and the desired power (z_1−β = 0.842 for 80% and 1.282 for 90%).

Formula

n is the number of participants in each arm, Δ is the difference in means to detect and σ is the common standard deviation.

Worked calculation for this trial

1. Observed difference Δ = -2.830; pooled standard deviation σ = 45.191.
2. n = 2 × (1.96 + 0.842)² × 45.191² / -2.830² = 4,002.8, rounded up to 4,003 participants per arm for 80% power.

The smaller-effect rows in the table above repeat the same calculation with the effect multiplied by 0.75 and 0.5 (for ratios, applied to the logarithm of the ratio).

R code

alpha <- 0.05
z_a   <- qnorm(1 - alpha / 2)          # two-sided
delta <- -2.83                      # observed difference in means
sigma <- 45.1908781171599                     # pooled standard deviation
n_per_arm <- function(power, frac = 1) {
  ceiling(round(2 * (z_a + qnorm(power))^2 * sigma^2 / (delta * frac)^2, 6))
}
for (f in c(1, 0.75, 0.5))
  cat(sprintf("%3.0f%% of observed effect: n per arm = %s (80%% power), %s (90%% power)\n", 100 * f,
              format(n_per_arm(0.80, f), big.mark = ","), format(n_per_arm(0.90, f), big.mark = ",")))

# Check against R's built-in function (t-based, so very slightly larger)
cat("power.t.test:", round(power.t.test(delta = delta, sd = sigma, power = 0.80)$n, 1), "\n")

# Simulation: exact two-sample t-test using simulated means and variances
set.seed(1669122)
n    <- n_per_arm(0.80)
reps <- 20000
m_diff <- rnorm(reps, delta, sigma * sqrt(2 / n))             # difference in sample means
s2     <- sigma^2 * rchisq(reps, 2 * (n - 1)) / (2 * (n - 1))   # pooled sample variance
tstat  <- m_diff / sqrt(s2 * 2 / n)
cat(sprintf("Simulated power at n = %s per arm: %.3f (%d replicates)\n", format(n, big.mark = ","), mean(abs(tstat) > qt(0.975, 2 * (n - 1))), reps))

Output from running the code

100% of observed effect: n per arm = 4,003 (80% power), 5,359 (90% power)
 75% of observed effect: n per arm = 7,117 (80% power), 9,527 (90% power)
 50% of observed effect: n per arm = 16,012 (80% power), 21,435 (90% power)
power.t.test: 4003.8 
Simulated power at n = 4,003 per arm: 0.805 (20000 replicates)

The simulation draws many sets of group means and variances at the planned sample size and counts how often the two-sample t-test rejects the null. It should land close to the target power; at very small required sample sizes it can fall below it, because the normal approximation is rough there.

14. Analyses Reported by the Sponsor

The registry reports sponsor analyses of treatment ratios for the primary endpoint. The ratio for Test Lozenge (A) versus Reference Lozenge is 0.96, with a 90% confidence interval of 0.93 to 0.99. The corresponding result for B is also 0.96, with interval 0.93 to 0.99. For C, the ratio is 0.94, with interval 0.91 to 0.97. The registry classifies these analyses as non-inferiority or equivalence, but the statistical method and decision margin are not reported in the registry record.

The simple recalculations use posted means, standard deviations, and group sizes to estimate unadjusted mean differences and 95% confidence intervals. They do not use participant-level crossover data and are not the sponsor’s reported analysis. As a result, the ratios and the recalculated differences should not be treated as interchangeable estimates. The treatment ratios are on a ratio scale; the recalculations are on an additive scale.

The registry record does not flag a discrepancy between the posted sponsor results and the recalculations. Nevertheless, the sponsor’s own analysis takes precedence for interpreting the trial’s planned treatment-ratio assessment. The recalculations are useful as a transparent check on the arm-level summaries, but they cannot reproduce the sponsor’s crossover model or establish the formal criteria for equivalence or non-inferiority. The registry does not report those model details or the margin needed to assess the sponsor’s formal classification independently.

15. Multiplicity, Missing Data and Analysis Populations

The primary endpoint involves comparisons of three prototypes with the reference. The registry reports sponsor treatment-ratio results for each primary contrast and also posts unadjusted recalculated p-values for the mean differences. No multiplicity procedure is reported in the registry record. If several contrasts are tested, the chance of at least one apparently unusual result can increase unless the analysis accounts for the number and structure of comparisons. The posted p-values should therefore not be treated as multiplicity-adjusted evidence.

The registry identifies the primary analysis population as per protocol and describes it as randomized participant profiles without a protocol deviation that would have led to exclusion of the data. The per-protocol group sizes are reported for each lozenge condition. The registry does not report a complete participant flow, the number or reasons for exclusions, the number of missing profiles, or how missing data were handled. It also does not explain whether other analysis populations were used for the sponsor’s results.

For a crossover study, period, sequence, and within-participant structure can affect analysis. The registry record does not report the model, treatment sequence allocation details, washout interval, carryover assessment, or how period effects were treated. The sponsor-reported treatment-ratio method is not specified. Without these details, readers cannot fully reproduce the analysis or determine how the crossover design was represented statistically.

The registry does not report an interim analysis plan, stopping rules, or the trial’s original sample-size assumptions. The planning illustrations elsewhere are separate calculations based on observed effects and stated generic assumptions; they do not fill in the trial’s original design rationale. The prespecified equivalence or non-inferiority margin is also not reported. Consequently, the formal interpretation of the sponsor’s classified analyses cannot be independently evaluated from the registry record alone.

16. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 1% reporting threshold.

The posted adverse-event figures show zero serious adverse events among the participants at risk in each group: Test Lozenge (A), 0 of 38; Test Lozenge (B), 0 of 37; Test Lozenge (C), 0 of 39; and Reference Lozenge, 0 of 38. The registry also reports zero participants with other adverse events in each of those groups. Death counts are not reported in the registry record.

These figures describe the recorded events in the posted groups; they do not establish that serious or other adverse events cannot occur. A study of this size and single-dose design provides limited information about uncommon events, longer exposure, or events outside the registry’s reporting period. The registry does not list serious adverse event terms, and no top serious-event terms are posted. That absence should not be interpreted as a complete account of all possible safety outcomes.

Because this is a crossover study, group counts across treatment conditions may include participants who received more than one lozenge condition. The counts should not be summed to create a total number of unique participants exposed. The registry record does not provide enough detail to determine how adverse events were attributed across treatment sessions or how repeated exposure was handled in the safety summaries. These figures are descriptive records of reported events, not a comprehensive safety comparison.

17. What the Result Does, and Does Not, Mean

The primary outcome compares nicotine exposure after three prototype lozenges with exposure after an internationally marketed reference lozenge. The posted means are relatively close, and the sponsor-reported treatment ratios are 0.96, 0.96, and 0.94. The simple mean-difference recalculations have confidence intervals that include zero and extend in both directions. Taken together, the posted results describe observed pharmacokinetic measurements and their uncertainty.

They do not establish that the lozenges are exactly equivalent. A formal equivalence conclusion depends on a prespecified margin and an analysis that evaluates whether the confidence interval falls within that margin. The registry labels the sponsor analyses as non-inferiority or equivalence but does not report the margin or statistical method. Those missing details prevent an independent assessment of the formal classification.

Likewise, the unadjusted p-values do not demonstrate equality when they are not small. A failure to show a difference is not proof that no difference exists. The intervals are important because they show that the unadjusted estimates remain compatible with a range of possible differences. Their interpretation is further limited by the absence of participant-level crossover information and the sponsor’s full model.

The study was conducted in fasted healthy male subjects after single doses, with plasma sampling through 12 hours. These conditions define the setting to which the results apply. The study does not directly measure smoking cessation, sustained use, or a longer-term clinical outcome. Although the registry lists Smoking Cessation as a condition, the endpoint reported is pharmacokinetic exposure. No medical or behavioral conclusion should be inferred from AUC alone.

The results also do not establish comparative safety beyond the event counts recorded in this study. Zero reported serious adverse events in the listed groups is a descriptive finding, not proof that risk is absent. Overall, the evidence is best read as a limited pharmacokinetic comparison with sponsor-reported ratio results and less design-specific recalculations that provide a separate view of uncertainty.

18. Why This Trial Matters Statistically

This trial is statistically interesting because it combines a four-way crossover design with comparisons among three prototype formulations and a reference. Crossover designs can make within-person comparisons informative, but only when the analysis accounts for the repeated treatment structure. The registry gives arm-level means and standard deviations as well as sponsor-reported treatment ratios, while leaving the sponsor’s model details unreported. That contrast illustrates why the reported design alone is not enough to reproduce an analysis.

It also shows why two statistical summaries of the same study can look different without directly contradicting one another. The recalculated mean differences use an additive scale and independent group summaries. The sponsor reports ratios with 90% confidence intervals and labels them as non-inferiority or equivalence analyses. Their estimates and intervals answer related but not identical questions. A prespecified margin is essential to interpreting a formal equivalence claim, and it is not reported in the registry record.

The primary outcome is a continuous pharmacokinetic measure with substantial observed variability. This emphasizes the value of examining uncertainty rather than relying on point estimates or p-values alone. It also highlights the limits of modest group sizes when effect estimates are small relative to variation, although the original sample-size justification is not reported.

Finally, the case demonstrates the boundary between pharmacokinetic evidence and clinical outcomes. AUC, peak timing, and elimination measures describe nicotine concentration behavior after dosing. They do not directly answer whether smoking cessation outcomes differ. Keeping the endpoint, design, analysis scale, and clinical question distinct is central to a careful statistical reading.

19. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

Several trial-specific limitations affect interpretation. The study was open label, so participants and study personnel were not masked according to the registry. The main endpoint is an objective plasma concentration-derived measure, but the registry does not explain whether open-label status could have affected procedures, sample handling, or other aspects of data collection.

The study included fasted healthy male subjects and evaluated single doses with blood sampling through 12 hours. Results from this setting do not by themselves describe other populations, repeated dosing, or longer-term outcomes. The registry does not report demographic detail beyond the population description or explain the basis for the study population.

The crossover design is a strength for within-person comparisons, but key details needed to assess it are missing. Treatment sequences, washout interval, period handling, carryover assessment, and the statistical model are not reported in the registry record. The summary-statistic recalculations cannot recover within-person covariance and should not be mistaken for a full crossover analysis.

The registry reports per-protocol endpoint group sizes but not complete participant flow, exclusion reasons, missing-data handling, or additional analysis populations. The original sample-size justification, interim analysis plan, multiplicity approach, equivalence or non-inferiority margin, and sponsor analysis method are also not reported. These gaps limit independent verification of the sponsor’s formal treatment-ratio interpretation.

Finally, the registry’s posted secondary results are incomplete: Tmax results are not reported, and some sponsor analyses are absent for secondary endpoints. Adverse-event counts are descriptive, death counts are not reported, and no serious-event terms are listed. The trial’s size and single-dose design cannot resolve uncommon or longer-term safety questions.

20. Related Tutorials

21. Related Statistical Calculators

22. Sources

• ClinicalTrials.gov: Pharmacokinetic Study of 4 mg Nicotine Lozenge. — NCT01669122.
• Registry record last updated 2015-01-22; status last verified 2014-10.
• Results first posted 2015-01-22.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

23. Record Summary

NCT01669122 is a completed Phase 2, randomized, open-label, single-center, four-way crossover study of three prototype 4 mg nicotine lozenges and an internationally marketed 4 mg reference lozenge. It enrolled 40 fasted healthy male subjects and assessed plasma nicotine after single doses.

The primary endpoint was AUC(0-t), with sponsor-reported treatment ratios of 0.96 for A, 0.96 for B, and 0.94 for C, each accompanied by a 90% confidence interval. Simple unadjusted mean-difference recalculations have intervals that include zero. Because the registry does not report the sponsor’s model or the equivalence/non-inferiority margin, the formal interpretation cannot be independently confirmed from the record alone.

Secondary pharmacokinetic outcomes include AUC(0-inf), Tmax, Kel, and half life. The registry reports no serious or other adverse events in the listed groups; death counts are not reported. The results describe single-dose pharmacokinetics and do not directly establish a smoking cessation outcome.